AD · Alzheimer’s disease

Alzheimer's disease

AD studies often fail when the model or observation window is mismatched. Plaque, Tau phosphorylation and neuroinflammation do not progress in lockstep, so a single time point rarely supports a complete conclusion.

5xFAD develops Aβ plaques early and is suited to anti-amyloid efficacy. rTg4510 models Tau phosphorylation and aggregation with a longer intervention window. The two pathways provide complementary evidence.

Our AD work spans multiple models, ages and sexes, combining plaque and Tau pathology with Iba1, GFAP, Aβ40 / Aβ42, CSF biomarkers and cognitive endpoints.

30+Completed AD projects
6Available models
1–18mAge coverage
♀ & ♂Sex-specific validation

Discuss a model study

Model strategy

Aβ / Tau pathology, neuroinflammation and cognition.

Match the model and study conditions to candidate mechanism, intervention stage and target tissue.

5xFAD

Aβ pathology, neuroinflammation and cognition

rTg4510

Tau phosphorylation and cognition

APP/PS1

Amyloid-plaque research

3×Tg-AD

Aβ and Tau co-pathology

P301S (PS19)

Tau aggregation and neurodegeneration

APOE4-Tg

APOE4-related inflammation and metabolism

Evaluation endpoints

01Aβ42 / ThS pathology burden
02Tau phosphorylation and protein expression
03Glial and inflammatory markers
04Morris water maze, Y-maze and novel-object recognition

Representative data

5xFAD mice · Aβ amyloid plaque progression | Longitudinal pathology from 1–12 months of age. Longitudinal progression of Aβ42 and ThS staining in the hippocampus of male and female 5xFAD mice at 4M / 6M / 8M / 12M, with a quantitative curve of plaque number versus age on the right and fluorescence co-staining for 5xFAD, Aβ1-42, GFAP and CD11b below. — 01
5xFAD mice · Aβ amyloid plaque progression | Longitudinal pathology from 1–12 months of age
Longitudinal progression of Aβ42 and ThS staining in the hippocampus of male and female 5xFAD mice at 4M / 6M / 8M / 12M, with a quantitative curve of plaque number versus age on the right and fluorescence co-staining for 5xFAD, Aβ1-42, GFAP and CD11b below.

rTg4510 mice · Tau pathology | Phosphorylation progression + cognitive impairment. Comparison of Tau5 / AT8 staining in 3-month-old rTg4510 and WT mice, brain-region images and Morris water maze escape latency curves (Day 1–6), with a statistical table of spatial memory at 7 months of age below (escape latency 28s vs 70s, target quadrant 31% vs 20%, p<0.001). — 02
rTg4510 mice · Tau pathology | Phosphorylation progression + cognitive impairment
Comparison of Tau5 / AT8 staining in 3-month-old rTg4510 and WT mice, brain-region images and Morris water maze escape latency curves (Day 1–6), with a statistical table of spatial memory at 7 months of age below (escape latency 28s vs 70s, target quadrant 31% vs 20%, p<0.001).

Efficacy evaluation case | Test article improves spatial memory impairment in 5xFAD (ICV administration). Morris water maze escape latency in 5xFAD mice: 48s in the Vehicle group and 34s in the ICV administration group. — 03
Efficacy evaluation case | Test article improves spatial memory impairment in 5xFAD (ICV administration)
Morris water maze escape latency in 5xFAD mice: 48s in the Vehicle group and 34s in the ICV administration group.

Project discussion & study design

Share candidate type, target, intended route and existing results so we can define primary endpoints, groups and study cadence.

View related service

Related research directions

Technical contact

Discuss your target, model or delivery question and learn about study plans, project scope and pricing.

+86 133 7528 3993 yijiusier@lewos.cn